NO20062739L - Kontrollert frigivining av topirimat i flytende doseringsform - Google Patents

Kontrollert frigivining av topirimat i flytende doseringsform

Info

Publication number
NO20062739L
NO20062739L NO20062739A NO20062739A NO20062739L NO 20062739 L NO20062739 L NO 20062739L NO 20062739 A NO20062739 A NO 20062739A NO 20062739 A NO20062739 A NO 20062739A NO 20062739 L NO20062739 L NO 20062739L
Authority
NO
Norway
Prior art keywords
controlled release
topirimate
dosage form
liquid dosage
methods
Prior art date
Application number
NO20062739A
Other languages
English (en)
Norwegian (no)
Inventor
Andrew C Lam
Liang-Chang Dong
Shaoling Li
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of NO20062739L publication Critical patent/NO20062739L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20062739A 2003-11-14 2006-06-13 Kontrollert frigivining av topirimat i flytende doseringsform NO20062739L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51995803P 2003-11-14 2003-11-14
PCT/US2004/037616 WO2005048981A1 (en) 2003-11-14 2004-11-12 Controlled release of topirimate in liquid dosage forms

Publications (1)

Publication Number Publication Date
NO20062739L true NO20062739L (no) 2006-08-14

Family

ID=34619401

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062739A NO20062739L (no) 2003-11-14 2006-06-13 Kontrollert frigivining av topirimat i flytende doseringsform

Country Status (13)

Country Link
US (1) US20050129765A1 (cg-RX-API-DMAC7.html)
EP (1) EP1684713A1 (cg-RX-API-DMAC7.html)
JP (1) JP2007511519A (cg-RX-API-DMAC7.html)
KR (1) KR20060120193A (cg-RX-API-DMAC7.html)
CN (1) CN1905857A (cg-RX-API-DMAC7.html)
AU (1) AU2004291081A1 (cg-RX-API-DMAC7.html)
CA (1) CA2545834A1 (cg-RX-API-DMAC7.html)
IL (1) IL175605A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA06005462A (cg-RX-API-DMAC7.html)
NO (1) NO20062739L (cg-RX-API-DMAC7.html)
TW (1) TW200528144A (cg-RX-API-DMAC7.html)
WO (1) WO2005048981A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200604882B (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
MXPA06002067A (es) * 2003-08-22 2006-08-11 Johnson & Johnson Suministro gradual de topiramato durante periodo prolongado.
WO2005065648A2 (en) * 2003-12-29 2005-07-21 Alza Corporation, Inc., Novel drug compositions and dosage forms of topiramate
AU2004312082A1 (en) * 2003-12-29 2005-07-21 Alza Corporation, Inc. Novel drug compositions and dosage forms
MX2007014713A (es) * 2005-05-25 2008-02-14 Janssen Pharmaceutica Nv Formulacion pediatrica de topiramato.
WO2008027557A2 (en) * 2006-08-31 2008-03-06 Spherics, Inc. Topiramate compositions and methods of enhancing its bioavailability
EP2394643B1 (en) 2006-11-17 2015-09-02 Supernus Pharmaceuticals, Inc. Sustained-release formulations of topiramate
EP2363113B1 (en) * 2006-12-04 2017-08-02 Supernus Pharmaceuticals, Inc. Enhanced immediate release formulations of topiramate
EP2219624A2 (en) * 2007-11-08 2010-08-25 Glaxo Group Limited Pharmaceutical formulations
US20120145572A1 (en) * 2009-04-20 2012-06-14 Ecole Polytechnique Federale De Lausanne (Epfl) Containers assembled in fluid and corresponding production
CN102579367B (zh) * 2012-03-23 2014-03-12 中国人民解放军军事医学科学院毒物药物研究所 托吡酯缓释药物组合物、其制备方法及用途
CN103316026B (zh) 2012-03-23 2016-05-11 中国人民解放军军事医学科学院毒物药物研究所 含芬特明和托吡酯的联合产品及其制备方法
EP2829270B1 (en) 2012-03-23 2020-11-11 Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China Joint product containing synephrine and topiramate
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
CN108379588B (zh) * 2018-03-05 2024-07-02 合肥合源药业有限公司 托吡酯组合物
US20210169844A1 (en) 2019-12-10 2021-06-10 Tulex Pharmaceuticals Inc. Compositions and methods for treating epilepsy, seizures and other conditions
US12290504B2 (en) 2023-04-11 2025-05-06 Tap Pharmaceuticals Ag Aqueous formulations of topiramate

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2707154A (en) * 1952-06-09 1955-04-26 Monsanto Chemicals Antioxidants and compositions containing same
US3173876A (en) * 1960-05-27 1965-03-16 John C Zobrist Cleaning methods and compositions
NL271831A (cg-RX-API-DMAC7.html) * 1960-11-29
US3276586A (en) * 1963-08-30 1966-10-04 Rosaen Filter Co Indicating means for fluid filters
US3546142A (en) * 1967-01-19 1970-12-08 Amicon Corp Polyelectrolyte structures
CH508415A (de) * 1967-10-27 1971-06-15 Hoffmann La Roche Antioxydative Mischung und deren Verwendung
US3573936A (en) * 1967-12-15 1971-04-06 Rayonier Inc Plicatic acid and thiodipropionic acid as antioxidants for use in animal fats and vegetable oils
US3541006A (en) * 1968-07-03 1970-11-17 Amicon Corp Ultrafiltration process
US3541005A (en) * 1969-02-05 1970-11-17 Amicon Corp Continuous ultrafiltration of macromolecular solutions
US3865108A (en) * 1971-05-17 1975-02-11 Ortho Pharma Corp Expandable drug delivery device
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4002173A (en) * 1974-07-23 1977-01-11 International Paper Company Diester crosslinked polyglucan hydrogels and reticulated sponges thereof
US4077407A (en) * 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4038434A (en) * 1976-03-12 1977-07-26 Howard Hall & Company Antioxidant stabilized edible compositions
US4111201A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system for delivering selected beneficial agents having varying degrees of solubility
US4207893A (en) * 1977-08-29 1980-06-17 Alza Corporation Device using hydrophilic polymer for delivering drug to biological environment
US4200098A (en) * 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4259323A (en) * 1980-03-24 1981-03-31 Hoffmann-La Roche Inc. Potassium chloride emulsion
IN159370B (cg-RX-API-DMAC7.html) * 1982-01-15 1987-05-09 Ciba Geigy Ag
US4513600A (en) * 1983-01-03 1985-04-30 The Minster Machine Company Cam actuated ejector for a shell press
US4783337A (en) * 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US4513006A (en) * 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
US4627850A (en) * 1983-11-02 1986-12-09 Alza Corporation Osmotic capsule
US4663148A (en) * 1984-03-21 1987-05-05 Alza Corporation Dispenser comprising telescopically engaging members
US4915949A (en) * 1987-07-13 1990-04-10 Alza Corporation Dispenser with movable matrix comprising a plurality of tiny pills
US5024842A (en) * 1988-04-28 1991-06-18 Alza Corporation Annealed coats
US4931285A (en) * 1988-04-28 1990-06-05 Alza Corporation Aqueous based pharmaceutical coating composition for dosage forms
US5006346A (en) * 1988-04-28 1991-04-09 Alza Corporation Delivery system
CA1340821C (en) * 1988-10-06 1999-11-16 Nobuyuki Fukazawa Heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components
US5126142A (en) * 1989-07-18 1992-06-30 Alza Corporation Dispenser comprising ionophore
US5324280A (en) * 1990-04-02 1994-06-28 Alza Corporation Osmotic dosage system for delivering a formulation comprising liquid carrier and drug
US5190765A (en) * 1991-06-27 1993-03-02 Alza Corporation Therapy delayed
US5252338A (en) * 1991-06-27 1993-10-12 Alza Corporation Therapy delayed
AU651244B2 (en) * 1991-09-19 1994-07-14 Mcneilab, Inc. Process for the preparation of chlorosulfate and sulfamate derivatives of 2,3:4,5-bis-0-(1-methylethylidene)-beta-D- fructopyranose and (1-methylcyclohexyl)methanol
US5643909A (en) * 1993-04-19 1997-07-01 Syntex (U.S.A.) Inc. 10,11-Methanodibenzosuberane derivatives
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
US5633011A (en) * 1994-08-04 1997-05-27 Alza Corporation Progesterone replacement therapy
US5614578A (en) * 1994-10-28 1997-03-25 Alza Corporation Injection-molded dosage form
US5824638A (en) * 1995-05-22 1998-10-20 Shire Laboratories, Inc. Oral insulin delivery
US6551613B1 (en) * 1998-09-08 2003-04-22 Alza Corporation Dosage form comprising therapeutic formulation
US6174547B1 (en) * 1999-07-14 2001-01-16 Alza Corporation Dosage form comprising liquid formulation
DE69915346T2 (de) * 1998-12-17 2004-07-22 Alza Corp., Mountain View Umwandlung von flüssigkeitsgefüllten gelatinkapseln in systeme mit gesteuerter wirkstoffabgabe durch mehrfache beschichtungen
US6342249B1 (en) * 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
US6559293B1 (en) * 2002-02-15 2003-05-06 Transform Pharmaceuticals, Inc. Topiramate sodium trihydrate
DE60322371D1 (de) * 2002-03-29 2008-09-04 Alza Corp Volumensparende arzneiform zur kontrollierten freisetzung
US20070243254A1 (en) * 2002-06-26 2007-10-18 David Edgren Novel drug compositions and dosage forms of topiramate
EP1534238A1 (en) * 2002-07-29 2005-06-01 ALZA Corporation Formulations and dosage forms for controlled delivery of topiramate

Also Published As

Publication number Publication date
JP2007511519A (ja) 2007-05-10
IL175605A0 (en) 2006-09-05
US20050129765A1 (en) 2005-06-16
TW200528144A (en) 2005-09-01
ZA200604882B (en) 2007-11-28
AU2004291081A1 (en) 2005-06-02
CN1905857A (zh) 2007-01-31
WO2005048981A1 (en) 2005-06-02
CA2545834A1 (en) 2005-06-02
MXPA06005462A (es) 2006-12-15
EP1684713A1 (en) 2006-08-02
KR20060120193A (ko) 2006-11-24

Similar Documents

Publication Publication Date Title
NO20064347L (no) Substituerte 1,2,3,4-tetrahydroisokinolinderivater
MA33044B1 (fr) Composition pharmaceutique contenant des derives de glucopyranosyl diphenylmethane, sa forme posologique galenique, son procede de preparation et ses utilisations pour une regulation glycemique amelioree chez un patient
NO20064584L (no) Tetrahydropyridoindolderivater
PA8596901A1 (es) Inhibidores de p38 y metodos de uso de ellos
SE0301700D0 (sv) Novel compounds
NO20052888L (no) Diamintriazoler anvendelige som inhibitorer av proteinkinaser
BRPI0509172A (pt) pelo menos uma entidade quìmica, composição farmacêutica, métodos para tratar um paciente, para inibir pelo menos uma enzima que utiliza atp, e para tratar pelo menos uma doença, uso de pelo menos uma entidade quìmica, e, método para a fabricação de um medicamento
NO20092637L (no) Fremgangsmater for behandling
CL2007000789A1 (es) Compuestos derivados de malonamida, inhibidores de la gamma-secretasa; proceso de preparacion; composicion farmaceutica; y su uso en el tratamiento de la enfermedad de alzheimer.
NO20073059L (no) 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists
MY142329A (en) Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents.
NO20060978L (no) Farmasoytiske blandingr for behandling av prematur ejakulasjon ved pulmonal inhalering
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
AR047841A1 (es) Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios
MY140840A (en) Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
CY1108794T1 (el) Σπειροκυκλικα παραγωγα κυκλοεξανιου
NO20050795L (no) Forbindelser, blandinger og fremgangsmater for utnyttelse av samme
EP2114925A4 (en) AZETIDINE ANALOGUE AIS NUCLEOSIDASE AND PHOSPHORYLASE HEMMER
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
WO2007143607A3 (en) Method of treating atrophic vaginitis
PA8719401A1 (es) Compuestos de tetrahidropiridotienopirimidina y metodos para su empleo
BRPI0508700A (pt) uso de sns-595, composição farmacêutica, e, pó liofilizado
CL2008002082A1 (es) Compuestos derivados de 6-fenil-1h-imidazo[4,5-c]piridina-4-carbonitrilo, inhibidores de catepsina s y catepsina k; composicion farmaceutica; y uso en el tratamiento de osteoporosis, aterosclerosis, inflamacion, entre otras enfermedades.
ATE375810T1 (de) Cyanoamid-verbindungen als nützliche malonyl-coa decarboxylase-hemmer
DK1370260T3 (da) Azoler, som malonyl-coa-decarboxylaseinhibitorer anvendelige som mataboliske modulatorer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application